{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:18:03Z","timestamp":1761855483273,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virus Eradication"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jve.2023.100319","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T21:29:12Z","timestamp":1677706152000},"page":"100319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2587-1385","authenticated-orcid":false,"given":"M.","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7762-7483","authenticated-orcid":false,"given":"C.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Schwanke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Krabb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.-T.","family":"Liebich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-8518","authenticated-orcid":false,"given":"D.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Burghart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gutic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"T.","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Haltmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2523-1708","authenticated-orcid":false,"given":"M.","family":"Gschwantler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9930","key":"10.1016\/j.jve.2023.100319_bib1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jve.2023.100319_bib2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","article-title":"The burden of liver disease in Europe: a review of available epidemiological data","volume":"58","author":"Blachier","year":"2013","journal-title":"J Hepatol"},{"issue":"21","key":"10.1016\/j.jve.2023.100319_bib3","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global elimination of chronic hepatitis","volume":"380","author":"Thomas","year":"2019","journal-title":"N Engl J Med"},{"issue":"10178","key":"10.1016\/j.jve.2023.100319_bib4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model","volume":"393","author":"Heffernan","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jve.2023.100319_bib5","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1128\/jcm.35.12.3274-3277.1997","article-title":"Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland","volume":"35","author":"Villano","year":"1997","journal-title":"J Clin Microbiol"},{"issue":"8","key":"10.1016\/j.jve.2023.100319_bib6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1086\/605947","article-title":"Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection","volume":"200","author":"Page","year":"2009","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.jve.2023.100319_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1 Suppl","key":"10.1016\/j.jve.2023.100319_bib8","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.jve.2023.100319_bib9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.jve.2023.100319_bib10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"20","key":"10.1016\/j.jve.2023.100319_bib11","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jve.2023.100319_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/2050640619835394","article-title":"High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients","volume":"7","author":"Chromy","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.jve.2023.100319_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugpo.2019.01.011","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy","volume":"66","author":"Grebely","year":"2019","journal-title":"Int J Drug Pol"},{"issue":"3","key":"10.1016\/j.jve.2023.100319_bib14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/MEG.0000000000001027","article-title":"Efficacy of ledipasvir\/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease","volume":"30","author":"Moser","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jve.2023.100319_bib15","doi-asserted-by":"crossref","first-page":"411-","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jve.2023.100319_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s10620-017-4749-x","article-title":"Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 Months post-treatment","volume":"63","author":"Chan","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"24","key":"10.1016\/j.jve.2023.100319_bib17","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jve.2023.100319_bib18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2021.11.025","article-title":"HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease","volume":"76","author":"Semmler","year":"2021","journal-title":"J Hepatol"},{"year":"2016","series-title":"Global Health Sector Strategy on Viral Hepatitis 2016-2021 towards Ending Viral Hepatitis","key":"10.1016\/j.jve.2023.100319_bib19"},{"issue":"5","key":"10.1016\/j.jve.2023.100319_bib20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","author":"Blach","year":"2022","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"1","key":"10.1016\/j.jve.2023.100319_bib21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s12879-019-4284-9","article-title":"Prevalence of hepatitis C infection among the general population and high-risk groups in the EU\/EEA: a systematic review update","volume":"19","author":"Han","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"13-14","key":"10.1016\/j.jve.2023.100319_bib22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00508-021-01898-9","article-title":"Outcomes of an HCV elimination program targeting the Viennese MSM population","volume":"133","author":"Jachs","year":"2021","journal-title":"Wien Klin Wochenschr"},{"issue":"5","key":"10.1016\/j.jve.2023.100319_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2468-1253(17)30045-6","article-title":"Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study","volume":"2","year":"2017","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"Suppl 5","key":"10.1016\/j.jve.2023.100319_bib24","doi-asserted-by":"crossref","first-page":"v39","DOI":"10.1093\/jac\/dkz455","article-title":"HepCare Europe: a service innovation project. HepCheck: enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening. A prospective multisite feasibility study","volume":"74","author":"Barror","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jve.2023.100319_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/add.14393","article-title":"Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs","volume":"114","author":"Grebely","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.jve.2023.100319_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugpo.2017.08.001","article-title":"Elimination of hepatitis C virus infection among PWID: the beginning of a new era of interferon-free DAA therapy","volume":"47","author":"Grebely","year":"2017","journal-title":"Int J Drug Pol"},{"issue":"4","key":"10.1016\/j.jve.2023.100319_bib27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis","volume":"72","author":"Hajarizadeh","year":"2020","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.jve.2023.100319_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jve.2023.100319_bib29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.jve.2023.100319_bib30","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/jvh.12857","article-title":"Directly observed therapy of chronic hepatitis C with ledipasvir\/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals","volume":"25","author":"Sch\u00fctz","year":"2018","journal-title":"J Viral Hepat"},{"year":"2020","series-title":"Bericht zur Drogensituation 2020","author":"Horvath","key":"10.1016\/j.jve.2023.100319_bib31"},{"year":"2021","series-title":"Bericht zur Drogensituation 2021","author":"Busch","key":"10.1016\/j.jve.2023.100319_bib32"},{"issue":"2","key":"10.1016\/j.jve.2023.100319_bib33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Cast\u00e9ra","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jve.2023.100319_bib34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"year":"2017","series-title":"A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report","key":"10.1016\/j.jve.2023.100319_bib35"},{"issue":"5","key":"10.1016\/j.jve.2023.100319_bib36","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jve.2023.100319_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cld.626","article-title":"Treatment of HCV in persons who inject drugs: treatment as prevention","volume":"9","author":"Grebely","year":"2017","journal-title":"Clinical liver disease"},{"issue":"3","key":"10.1016\/j.jve.2023.100319_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229239","article-title":"Directly observed therapy for HCV with glecaprevir\/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria","volume":"15","author":"Schmidbauer","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jve.2023.100319_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252274","article-title":"Directly observed therapy at opioid substitution facilities using sofosbuvir\/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy","volume":"16","author":"Schmidbauer","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jve.2023.100319_bib40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: the role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antivir Res"},{"issue":"9","key":"10.1016\/j.jve.2023.100319_bib41","doi-asserted-by":"crossref","first-page":"594","DOI":"10.7326\/M18-1715","article-title":"Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial","volume":"170","author":"Akiyama","year":"2019","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.jve.2023.100319_bib42","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/cid\/ciz546","article-title":"Outcomes of treatment for hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs","volume":"70","author":"Wade","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jve.2023.100319_bib43","first-page":"P61","article-title":"Let's end hepatitis C in Vienna\u201d - the first HCV elimination program targeting homeless and people without medical insurance in Vienna","volume":"58","author":"Schwarz","year":"2020","journal-title":"Z Gastroenterol"},{"issue":"9-10","key":"10.1016\/j.jve.2023.100319_bib44","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00508-020-01790-y","article-title":"Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence","volume":"133","author":"Steininger","year":"2021","journal-title":"Wien Klin Wochenschr"}],"container-title":["Journal of Virus Eradication"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664023000055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664023000055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:12:52Z","timestamp":1761855172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2055664023000055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2055664023000055"],"URL":"https:\/\/doi.org\/10.1016\/j.jve.2023.100319","relation":{},"ISSN":["2055-6640"],"issn-type":[{"type":"print","value":"2055-6640"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Virus Eradication","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jve.2023.100319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100319"}}